QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=D6CE45891B758B23072D12349DA813EB;jsessionid=A78ED1FEEC9A13DD17CCC8E3368A4B4D;jsessionid=18A6E535F8253C80572B1F5ACAEBD5AC;jsessionid=4535FD7B0284BE655FA39BA9A4830C2E;jsessionid=1D4E65B379FFEBAC74AF27D7550C85DC;jsessionid=791BB5EA7D95854CDEEAAE56D5F40B99;jsessionid=E13C01F2F011016791296966E2F98D00 (gene)

1. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
2. Missense mutation in ATXN2 gene (c.2860C > T) in an amyotrophic lateral sclerosis patient with aggre…
3. The RNA-binding protein and stress granule component ATAXIN-2 is expressed in mouse and human tissue…
4. Ataxin-2 gene: a powerful modulator of neurological disorders.
5. Antagonistic roles for Ataxin-2 structured and disordered domains in RNP condensation.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=D6CE45891B758B23072D12349DA813EB;jsessionid=A78ED1FEEC9A13DD17CCC8E3368A4B4D;jsessionid=18A6E535F8253C80572B1F5ACAEBD5AC;jsessionid=4535FD7B0284BE655FA39BA9A4830C2E;jsessionid=1D4E65B379FFEBAC74AF27D7550C85DC;jsessionid=791BB5EA7D95854CDEEAAE56D5F40B99;jsessionid=E13C01F2F011016791296966E2F98D00